Harrow Closes Acquisition of TYRVAYA®
Harrow (HROW) completed its $30M acquisition of TYRVAYA nasal spray from Viatris, with up to $70M in milestone payments. TYRVAYA, approved for dry eye disease, complements Harrow's VEVYE product. Harrow expects $30M+ revenue from TYRVAYA in 2027, with 40 Viatris employees joining its team.
How this was made
The 30-second read
Why it matters
The transaction expands Harrow's portfolio, potentially increasing 2027 revenue by over $30M and enhancing market share in the dry‑eye segment.
Market read
The deal is a material M&A event for Harrow, likely driving short‑term stock movement and longer‑term revenue growth.
What to watch
Milestone payments are contingent on sales; slower adoption or reimbursement challenges could limit upside.
Background
Harrow, a Nasdaq‑listed ophthalmic disease management company, announced the closing of its purchase of TYRVAYA, a nasal spray for dry‑eye disease, from Viatris.
Ticker impact
Harrow closed its acquisition of TYRVAYA nasal spray from Viatris for $30M cash, with up to $70M contingent milestones, expanding its dry‑eye portfolio.
likely upside as the market prices in added revenue and pipeline expansion
Acquisition of a commercial product with $30M upfront and potential $100M total consideration is material for a small‑cap biotech, prompting immediate price appreciation.
Market effects
Strengthens the ophthalmology/ocular‑surface sector with consolidation and expanded product offerings.
U.S. dry‑eye market sees increased competition; limited impact on Asian markets where Viatris retains Japan rights.
Adds to the broader trend of specialty pharma M&A, but limited global market effect beyond the eye‑care niche.
Counterpoint
The acquisition may strain Harrow's cash balance and integration risk could offset revenue upside.
Key entities
- CompanyHarrow
Nasdaq‑listed provider of ophthalmic disease management solutions.
- CompanyViatris
Global healthcare company selling TYRVAYA rights in Japan.
